Changes in Hong Kong stocks | Kangfang Biotech (09926) rose nearly 6% Evarosi Global Phase III Harmoni Research OS update, and the curative effects are highly consistent in Eastern and Western populations

The Zhitong Finance App learned that Kangfang Biotech (09926) rose nearly 6%. As of press release, it had risen 5.86% to HK$104.7, with a turnover of HK$648 million.

According to the news, on July 22, EST, Kangfang Biotech's overseas partner Summit Therapeutics announced that the latest OS analysis results of the Evosi Global Multi-Center Phase III Harmoni Study showed that OS continued to improve to HR = 0.76 for all Intended Treatment (ITT) people, and OS benefits for Western people also further increased to HR = 0.76. It is highly consistent with the OS benefits previously studied by Harmoni-A in China. Follow-up was extended to 23.2 months in the Western population, benefiting from continued improvement in follow-up. Summit has submitted updated data to the FDA to continue to advance Evosi's potential approved BLA application in the US.

China Merchants Securities believes that this data update not only verifies the long-term immunization benefits of Iwasi, but also mitigates previous concerns that “European and American patients are uncertain about OS benefits, and the results may be inconsistent between Asia and the West”. It is a substantial de-risking of the global extrapolation of Evosi, and also positively supports the FDAPDUFA of November 14. The bank continues to be optimistic about Kang Fang AK112 as the cornerstone drug for next-generation IO treatment and the fulfillment of overseas value. Harmoni's updated OS follow-up data once again confirms that European and American people can repeat the dominant data of the Chinese population.